The aim of the DIALA project was to demonstrate the feasibility of structured treatment and teaching programs for type 2 diabetic patients in order to improve the overall quality of care. The investigation was carried out in Upper Austria. The results and findings of structured treatment were evaluated as well as the associated costs of current diabetes management. 19 practitioners were recruited. From the beginning of January 2002 to the end of December 2003, a total of 343 diabetics were registered, and clinical and economic data were collected on all diabetic patients who visited the primary care offices during the period of 24 months. The aims of treatment were discussed between practitioners and patients, routine examinations were carried out quarterly, and all data were recorded using a diabetes care card. All the patients participating in the project were given the opportunity to take part in a diabetes self-management teaching programme. There was an obvious correlation between information and treatment on the one hand and clinical results, as measured by HbA1c, blood pressure levels and body weight on the other. Costs were calculated in a standardized way, and showed a reduction in expense as a result of the structured treatment and cost savings amounting to EUR 620 per annum and patient. The hospital admission rate for cases with diabetes mellitus as the primary diagnosis was considerably reduced. Our results indicate that establishing a structured treatment and teaching programme can improve the quality of diabetes therapy in primary care and influence the rate at which physicians admit patients to hospital.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10354-005-0197-x | DOI Listing |
JAMA Netw Open
January 2025
Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey.
Importance: Clinical trials are vital for advancing cancer treatments and improving patient outcomes. Understanding the factors that influence participants' decision-making is critical for enhancing trial recruitment.
Objective: To evaluate the attitudes of patients with cancer and their relatives toward clinical trial participation, identifying key barriers and motivators that affect their willingness to engage in such trials.
Sociol Health Illn
February 2025
Tampere Centre for Science, Technology and Innovation Studies, Faculty of Social Sciences, Tampere University, Tampere, Finland.
Multimorbidity, meaning multiple long-term conditions impacting a person's health, has become a rising societal and public health issue. The article contributes to the sociological study of chronic illness and multimorbidity by analysing how the blurriness of illnesses and entanglement of symptoms in multimorbidity is experienced and negotiated by people with coexisting chronic conditions. Drawing on qualitative interviews with people who live with endometriosis, fibromyalgia or hormonal migraine in Finland, we show how people with multiple chronic conditions distinguish between evolving symptoms based on past embodied experiences to make decisions about how to best manage their health.
View Article and Find Full Text PDFFASEB J
January 2025
Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
With the emergence of high-quality sequencing technologies, further research on transcriptomes has become possible. Circular RNA (circRNA), a novel type of endogenous RNA molecule with a covalently closed circular structure through "back-splicing," is reported to be widely present in eukaryotic cells and participates mainly in regulating gene and protein expression in various ways. It is becoming a research hotspot in the non-coding RNA field.
View Article and Find Full Text PDFMol Divers
January 2025
Department of Biochemistry, University of Delhi South Campus, Benito Juarez Road, Dhaula Kuan, New Delhi, 110021, India.
Nanobodies or variable antigen-binding domains (VH) derived from heavy chain-only antibodies (HcAb) occurring in the Camelidae family offer certain superior physicochemical characteristics like enhanced stability, solubility, and low immunogenicity compared to conventional antibodies. Their efficient antigen-binding capabilities make them a preferred choice for next-generation small biologics. In the present work, we design an anti-SARS-CoV-2 bi-paratopic nanobody drug conjugate by screening a nanobody database.
View Article and Find Full Text PDFMol Divers
January 2025
Center of Bioinformatics, College of Life Sciences, Northwest Agriculture and Forestry University, Yangling, 712100, Shaanxi, China.
Melanoma, a highly aggressive skin cancer, remains a significant cause of mortality despite advancements in therapeutic strategies. There is an urgent demand for developing vaccines that can elicit strong and comprehensive immune responses against this malignancy. Achieving this goal is crucial to enhance the efficacy of immunological defense mechanisms in combating this disease.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!